Michio Imamura Selected Research

Pharmaceutical Preparations

8/2019	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
11/2015	Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
4/2015	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.
10/2014	[A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir/peginterferon/ribavirin].
12/2007	Successful treatment of an entecavir-resistant hepatitis B virus variant.
11/2006	Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michio Imamura Research Topics

Disease

79	Infections 10/2022 - 03/2005
64	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 09/2002
49	Chronic Hepatitis C 01/2021 - 07/2006
26	Neoplasms (Cancer) 10/2021 - 05/2007
22	Fibrosis (Cirrhosis) 07/2022 - 12/2004
22	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 06/2004
18	Chronic Hepatitis B 10/2022 - 02/2006
14	Neoplasm Metastasis (Metastasis) 10/2021 - 11/2011
14	Hepatitis C 09/2020 - 05/2009
11	Liver Diseases (Liver Disease) 10/2022 - 09/2010
11	Hepatitis B 01/2021 - 11/2006
9	Hepatitis 01/2021 - 07/2006
8	Thrombosis (Thrombus) 10/2021 - 11/2011
6	Hepatic Encephalopathy 11/2020 - 07/2013
6	Non-alcoholic Fatty Liver Disease 08/2020 - 03/2014
6	Disease Progression 04/2020 - 12/2007
6	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2018 - 07/2010
4	Insulin Resistance 03/2022 - 12/2014
4	Chronic Hepatitis (Chronic Active Hepatitis) 12/2020 - 03/2017
4	Type 2 Diabetes Mellitus (MODY) 01/2018 - 03/2014
3	Liver Neoplasms (Liver Cancer) 10/2022 - 05/2009
3	Viremia 12/2021 - 11/2005
3	Inflammation (Inflammations) 07/2019 - 01/2005
3	Acute Liver Failure (Fulminant Hepatic Failure) 12/2017 - 08/2014
3	Anemia 06/2017 - 06/2011
3	Esophageal and Gastric Varices (Esophageal Varices) 07/2013 - 03/2009
2	Fatty Liver 07/2022 - 05/2016
2	Hypoglycemia (Reactive Hypoglycemia) 03/2022 - 02/2017
2	Glucose Intolerance 03/2022 - 02/2017
2	Liver Failure 02/2021 - 06/2008
2	Necrosis 01/2021 - 01/2018
2	Carcinogenesis 11/2020 - 07/2006
2	Varicose Veins (Varicose Vein) 11/2020 - 05/2002
2	Microsatellite Instability 10/2020 - 07/2020

Drug/Important Bio-Agent (IBA)

53	InterferonsIBA 12/2020 - 07/2006
36	Ribavirin (Virazole)FDA LinkGeneric 12/2020 - 01/2007
29	Antiviral Agents (Antivirals)IBA 02/2022 - 05/2012
18	daclatasvirIBA 01/2020 - 01/2014
17	lenvatinibIBA 04/2022 - 01/2019
16	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 12/2014
16	asunaprevirIBA 01/2020 - 01/2015
13	Proteins (Proteins, Gene)FDA Link 10/2022 - 11/2006
11	RNA (Ribonucleic Acid)IBA 01/2020 - 06/2008
10	AntigensIBA 01/2021 - 02/2006
9	telaprevirIBA 06/2016 - 09/2011
8	Alanine Transaminase (SGPT)IBA 01/2021 - 08/2007
8	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2005
8	SofosbuvirIBA 12/2020 - 04/2015
7	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2021 - 01/2017
6	Pharmaceutical PreparationsIBA 08/2019 - 11/2006
6	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2018 - 07/2010
6	Lamivudine (Epivir)FDA Link 08/2010 - 11/2005
5	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 03/2014
5	NucleosidesIBA 01/2022 - 05/2007
5	EnzymesIBA 02/2021 - 05/2007
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 07/2012
5	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 08/2009
5	CytokinesIBA 01/2020 - 09/2010
4	Cisplatin (Platino)FDA LinkGeneric 06/2022 - 09/2002
4	Hemoglobins (Hemoglobin)IBA 03/2022 - 06/2011
4	regorafenibIBA 01/2021 - 09/2018
4	Protease Inhibitors (Protease Inhibitor)IBA 04/2020 - 07/2010
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
4	NucleotidesIBA 01/2019 - 10/2013
4	SimeprevirIBA 03/2017 - 06/2016
3	Bevacizumab (Avastin)FDA Link 04/2022 - 08/2021
3	atezolizumabIBA 04/2022 - 08/2021
3	glecaprevir and pibrentasvirIBA 01/2021 - 09/2019
3	Immunoglobulin G (IgG)IBA 01/2021 - 06/2008
3	Prothrombin (Factor II)IBA 01/2021 - 12/2014
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2020
3	velpatasvirIBA 12/2020 - 09/2019
3	Fetal Proteins (Fetoprotein)IBA 11/2020 - 07/2016
3	ChemokinesIBA 07/2019 - 01/2011
3	Tumor Biomarkers (Tumor Markers)IBA 01/2019 - 04/2015
3	entecavir FDA Link 12/2018 - 12/2007
3	ledipasvirIBA 12/2018 - 04/2017
3	Hepatitis B e AntigensIBA 01/2018 - 07/2006
3	Complementary DNA (cDNA)IBA 05/2017 - 01/2011
3	Interferon LambdaIBA 09/2015 - 02/2011
3	MicroRNAs (MicroRNA)IBA 03/2015 - 01/2012
3	Amino Acids FDA Link 09/2011 - 01/2005
3	Interferon-alpha (Interferon Alfa)IBA 10/2007 - 01/2007
2	Blood Glucose (Blood Sugar)IBA 03/2022 - 01/2018
2	Circulating Tumor DNAIBA 06/2021 - 09/2015
2	Immune Checkpoint InhibitorsIBA 02/2021 - 10/2020
2	Prednisolone (Predate)FDA LinkGeneric 02/2021 - 01/2014
2	Methylprednisolone FDA LinkGeneric 01/2021 - 01/2014
2	GlucocorticoidsIBA 01/2021 - 01/2014
2	HLA-DQB1 antigen (HLA DQB1)IBA 12/2020 - 01/2013
2	pembrolizumabIBA 10/2020 - 07/2020

Therapy/Procedure

93	Therapeutics 10/2022 - 07/2006
16	Drug Therapy (Chemotherapy) 06/2022 - 11/2011
16	Liver Transplantation 01/2021 - 08/2008
6	Radiotherapy 10/2021 - 11/2011
4	Hepatectomy 08/2019 - 12/2014
4	Surgical Portasystemic Shunt (Portosystemic Shunt) 08/2019 - 07/2013
2	Glycemic Control 03/2022 - 03/2014
2	Gastrectomy 07/2021 - 06/2011
2	Retreatment 12/2020 - 04/2018